1.Knowledge, Behaviors and Prevalence of Reproductive Tract Infections: A Descriptive Study on Rural Women in Hunchun, China.
Chunyu LI ; Hae Ra HAN ; Jong Eun LEE ; Myungken LEE ; Youngja LEE ; Miyong T KIM
Asian Nursing Research 2010;4(3):122-129
PURPOSE: The aim of the study was to assess the prevalence, knowledge and behavior about reproductive tract infections (RTIs) among rural Chinese women in Hunchun, China. METHODS: The study employed a cross-sectional research design with a convenience sample of 190 participants who had received microfinancing. Data were collected by trained research staff, utilizing face to face interviews and physical examinations. RESULTS: About 1 in 5 participants (20.3%) had had more than 5 pregnancies and 26.7% had had 3 or more abortions. More than half (57.3%) of study participants had an RTI at the time of examination, and 92.3% reported having had at least one RTI symptom. Nearly half (49.6%) of the women who exhibited RTI symptoms reported no utilization of any healthcare services. Age, number of pregnancies, RTI knowledge, and behavior were found to be significant correlates in the sample. CONCLUSIONS: The prevalence of RTI among low-income rural Chinese women were extremely high, indicating the urgent need for effective and culturally sensitive health education, particularly targeted to the poor rural population.
Asian Continental Ancestry Group
;
China
;
Delivery of Health Care
;
Female
;
Health Education
;
Humans
;
Pregnancy
;
Prevalence
;
Reproductive Tract Infections
;
Research Design
;
Rural Population
2.Low-Dose Bisphenol A Increases Bile Duct Proliferation in Juvenile Rats: A Possible Evidence for Risk of Liver Cancer in the Exposed Population?.
Ji Seong JEONG ; Ki Taek NAM ; Buhyun LEE ; Aryo Dimas PAMUNGKAS ; Daeun SONG ; Minjeong KIM ; Wook Joon YU ; Jinsoo LEE ; Sunha JEE ; Youngja H PARK ; Kyung Min LIM
Biomolecules & Therapeutics 2017;25(5):545-552
Increasing concern is being given to the association between risk of cancer and exposure to low-dose bisphenol A (BPA), especially in young-aged population. In this study, we investigated the effects of repeated oral treatment of low to high dose BPA in juvenile Sprague-Dawley rats. Exposing juvenile rats to BPA (0, 0.5, 5, 50, and 250 mg/kg oral gavage) from post-natal day 9 for 90 days resulted in higher food intakes and increased body weights in biphasic dose-effect relationship. Male mammary glands were atrophied at high dose, which coincided with sexual pre-maturation of females. Notably, proliferative changes with altered cell foci and focal inflammation were observed around bile ducts in the liver of all BPA-dosed groups in males, which achieved statistical significance from 0.5 mg/kg (ANOVA, Dunnett’s test, p<0.05). Toxicokinetic analysis revealed that systemic exposure to BPA was greater at early age (e.g., 210-fold in C(max), and 26-fold in AUC at 50 mg/kg in male on day 1 over day 90) and in females (e.g., 4-fold in C(max) and 1.6-fold in AUC at 50 mg/kg vs. male on day 1), which might have stemmed from either age- or gender-dependent differences in metabolic capacity. These results may serve as evidence for the association between risk of cancer and exposure to low-dose BPA, especially in young children, as well as for varying toxicity of xenobiotics in different age and gender groups.
Animals
;
Area Under Curve
;
Bile Ducts*
;
Bile*
;
Body Weight
;
Child
;
Female
;
Humans
;
Inflammation
;
Liver Neoplasms*
;
Liver*
;
Male
;
Mammary Glands, Human
;
Rats*
;
Rats, Sprague-Dawley
;
Toxicokinetics
;
Xenobiotics
3.The effects of dietary self-monitoring intervention on anthropometric and metabolic changes via a mobile application or paper-based diary: a randomized trial
Taiyue JIN ; Gyumin KANG ; Sihan SONG ; Heejin LEE ; Yang CHEN ; Sung-Eun KIM ; Mal-Soon SHIN ; Youngja H PARK ; Jung Eun LEE
Nutrition Research and Practice 2023;17(6):1238-1254
BACKGROUND/OBJECTIVES:
Weight loss via a mobile application (App) or a paper-based diary (Paper) may confer favorable metabolic and anthropometric changes.
SUBJECTS/METHODS:
A randomized parallel trial was conducted among 57 adults whose body mass indices (BMIs) were 25 kg/m 2 or greater. Participants randomly assigned to either the App group (n = 30) or the Paper group (n = 27) were advised to record their foods and supplements through App or Paper during the 12-week intervention period. Relative changes of anthropometries and biomarker levels were compared between the 2 intervention groups.Untargeted metabolic profiling was identified to discriminate metabolic profiles.
RESULTS:
Out of the 57 participants, 54 participants completed the trial. Changes in body weight and BMI were not significantly different between the 2 groups (P = 0.11). However, body fat and low-density lipoprotein (LDL)-cholesterol levels increased in the App group but decreased in the Paper group, and the difference was statistically significant (P = 0.03 for body fat and 0.02 for LDL-cholesterol). In the metabolomics analysis, decreases in methylglyoxal and (S)-malate in pyruvate metabolism and phosphatidylcholine (lecithin) in linoleic acid metabolism from pre- to post-intervention were observed in the Paper group.
CONCLUSIONS
In the 12-week randomized parallel trial of weight loss through a App or a Paper, we found no significant difference in change in BMI or weight between the App and Paper groups, but improvement in body fatness and LDL-cholesterol levels only in the Paper group under the circumstances with minimal contact by dietitians or health care providers.Trial Registration: Clinical Research Information Service Identifier: KCT0004226
4.Differences in Clinical Responses to Ustekinumab Treatment among Body Regions: Results from a Real-World Prospective, Observational, and Multi-Center Study in Korea
Sang Wook SON ; Dae Young YU ; Youngdoe KIM ; Hyo Hyun AHN ; Yong Hyun JANG ; Joo Young ROH ; Young Bok LEE ; Ji Yeoun LEE ; Myung Hwa KIM ; YoungJa LEE ; Gyeong-Hun PARK ; Hyun-Sun YOON ; Sang Woong YOUN ;
Annals of Dermatology 2022;34(1):14-21
Background:
In psoriasis treatment, not all body regions improve simultaneously after clinical interventions.
Objective:
This study was aimed at evaluating clinical responses across body regions, which may differentially influence patient treatment plans.
Methods:
This prospective, observational, and multi-center study was conducted in Koreans who adhered to ustekinumab treatment based on criteria per local label and reimbursement guidelines. A total of 581 were included in this analysis.
Results:
The mean (±standard deviation) psoriasis area severity index (PASI) score at baseline, age, disease duration, and body surface area (%) were 18.9±9.69, 44.2±13.29 years, 11.3±9.65 years, and 27.8±17.83, respectively. Across the head and neck, upper extremities, trunk, and lower extremities, the correlation between the PASI sub-scores for the upper and lower extremities was the highest (r=0.680). The mean PASI sub-score for the lower extremities was the highest at baseline. PASI90 and PASI100 scores were the highest for the head and neck region, indicating the highest response rates, while those for the lower extremities were consistently low at all visits.
Conclusion
We found differences in regional ustekinumab responses, with the lower extremities being the most difficult to treat. These findings should be considered in psoriasis treatment.
5.Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease:A Multicenter, Phase 3 Study (BEGIN)
Jae Hee CHEON ; Hyun-Soo KIM ; Dong Soo HAN ; Sung Kook KIM ; Sung Jae SHIN ; Joo Sung KIM ; Byong Duk YE ; Geun Am SONG ; YoungJa LEE ; Youngdoe KIM ; Yoosun LEE ; Won Ho KIM ;
Gut and Liver 2023;17(5):777-785
Background/Aims:
To date, there is no prospective study that specifically investigated the efficacy of infliximab in intestinal Behçet’s disease (BD). This study evaluated the efficacy of infliximab in patients with moderate-to-severe active intestinal BD that are refractory to conventional therapies.
Methods:
This phase 3, interventional, open-label, single-arm study evaluated clinical outcomes of infliximab treatment in patients with moderate-to-severe intestinal BD. The coprimary endpoints were clinical response, decrease in disease activity index for intestinal BD (DAIBD) score ≥20 from weeks 0 to 8 for the induction therapy and week 32 for the maintenance therapy.
Results:
A total of 33 patients entered the induction therapy and were treated with infliximab 5 mg/kg intravenously at weeks 0, 2, and 6. The mean DAIBD score changed from 90.8±40.1 at week 0 to 40.3±36.4 at week 8, with a significant mean change of 50.5±36.4 (95% confidence interval, 37.5 to 63.4; p<0.001). Thirty-one (93.9%) continued to receive 5 mg/kg infliximab every 8 weeks during the maintenance therapy. The mean change in the DAIBD score after the maintenance therapy was statistically significant (61.5±38.5; 95% confidence interval, 46.0 to 77.1; p<0.001, from weeks 0 to 32). The proportion of patients who maintained a clinical response was 92.3% at week 32. No severe adverse reactions occurred during the induction and maintenance therapies.
Conclusions
This study provided evidence that infliximab 5 mg/kg induction and maintenance therapies are efficacious and well-tolerated in patients with moderate-to-severe active intestinal BD. (ClinicalTrials.gov identifier: NCT02505568)